Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in transplant-ineligible patients (Pts) with newly diagnosed multiple myeloma (NDMM): Clinical assessment of key subgroups of the phase 3 MAIA study Meeting Abstract
| Authors: | Moreau, P.; Facon, T.; Usmani, S.; Bahlis, N. J.; Raje, N.; Plesner, T.; Orlowski, R. Z.; Basu, S.; Nahi, H.; Hulin, C.; Quach, H.; Goldschmidt, H.; O'Dwyer, M.; Perrot, A.; Venner, C. P.; Weisel, K.; Tiab, M.; Macro, M.; Frenzel, L.; Leleu, X.; Pei, H.; Krevvata, M.; Carson, R.; Borgsten, F.; Kumar, S. K. |
| Abstract Title: | Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in transplant-ineligible patients (Pts) with newly diagnosed multiple myeloma (NDMM): Clinical assessment of key subgroups of the phase 3 MAIA study |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 7297 |
| End Page: | 7300 |
| Language: | English |
| ACCESSION: | WOS:000893230300135 |
| DOI: | 10.1182/blood-2022-163494 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
